Skip to main content

Table 2 Serum testosterone on each days after switching to lueprolide

From: Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist

   Day 0 Day 1 Day 2 Day 5 Day 7
ECLIA Total (n = 39) 7.5 ± 5.8 19.7 ± 27.5 17.4 ± 18.2 7.0 ± 4.8 6.7 ± 4.6
  Surge (-)      
  Total (n = 36) 7.6 ± 6.0 13.5 ± 10.6 14.3 ± 11.2 7.1 ± 4.8 6.8 ± 4.7
  3 m group (n = 9) 8.2 ± 6.8 11.9 ± 10.6 11.9 ± 11.4 7.9 ± 5.7 6.9 ± 5.0
  2 m group (n = 9) 6.0 ± 5.6 10.6 ± 11.9 9.0 ± 8.0 6.0 ± 5.7 6.3 ± 5.6
  1 m group (n = 19) 8.2 ± 5.9 15.7 ± 5.9 18.2 ± 11.5 7.2 ± 4.0 7.1 ± 4.1
  Surge (+)      
  No.10 (3 m) 10.0 161.0 88.0 3.0 3.0
  No.18 (2 m) 3.0 63.0 69.0 3.0 3.0
  No.30 (1 m) 3.0 59.0 5.0 12.0 9.0
LC-MS/MS Total (n = 36) 8.6 ± 4.4 24.1 ± 25.3 22.6 ± 20.6 8.6 ± 2.7 8.0 ± 3.0
  Surge (-)      
  Total (n = 33) 7.9 ± 3.0 17.9 ± 10.3 19.1 ± 13.4 8.4 ± 2.6 7.6 ± 2.6
  3 m group (n = 9) 8.6 ± 3.3 15.7 ± 12.3 15.4 ± 11.5 8.4 ± 3.4 8.0 ± 3.1
  2 m group (n = 8) 6.4 ± 2.6 14.9 ± 12.5 11.1 ± 11.1 6.8 ± 2.7 6.6 ± 3.2
  1 m group (n = 16) 8.3 ± 2.9 20.8 ± 7.4 24.4 ± 13.7 9.2 ± 1.6 7.9 ± 1.9
  Surge (+)      
  No.10 (3 m) 28.0 142.0 93.0 12.0 16.0
  No.18 (2 m) 12.0 72.0 80.0 9.0 12.0
  No.30 (1 m) 7.0 63.0 7.0 12.0 9.0
  1. Data are presented as means ± SD unless indicated otherwise
  2. ECLIA electrochemiluminescence Immunoassay; LC-MS/MS liquid chromatography-tandem mass spectrometry; surge (-) means a testosterone surge of down to 50 ng/dl was observed, surge (+) means a testosterone surge of up to 50 ng/dl was observed